Advaxis Announces Abstracts Accepted for Poster Presentation at ASCO Annual Meeting 2012
PRINCETON, N.J.--(BUSINESS WIRE)--May 2, 2012 - Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV have been selected for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2012 in Chicago, IL, from June 1-5, 2012, at the McCormick Place Convention Center.
The poster entitled “ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer” will present updated safety, tumor response, and survival data from the ongoing randomized Phase 2 trial of ADXS-HPV (ADXS11-001) with or without cisplatin. A second poster entitled “A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265)” will describe the trial design for a US study being conducted by the Gynecologic Oncology Group. Both trials are in the same type of patient population with overall survival as the primary endpoint. Abstracts will be released on or around May 16 and will be available at www.asco.org.; additional data will be available following the presentations on Sunday, June 3, 2012.
“We are excited to have the opportunity to present both of these trials at ASCO and to present new data which continue to build upon the data previously reported in January, 2012. We are encouraged by the continued interest in ADXS-HPV by the medical community given the investigators, institutions, and cooperative groups that are evaluating this immunotherapy,” commented Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.
ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Contact: Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
Posted: May 2012